112

4959211

PATENT ABSTRACTS

P R O C E S S F O R T H E P R O D U C T I O N O N A N A N T I V I R A L V A C C I N E ,

P A R T I C U L A R L Y A N T I - F O O T A N D M O U T H D I S E A S E V A C C I N E

Jorge H Lombardo, Eduardo E Smolko, Rodolfo A Ugalde, Scholein Rivenson, 1244 Moreno, Argentina

The instant invention relates to a process in which important improvements are introduced in virus production and inactivation steps, as well as in the vaccine formulation step. The virus is reproduced in animals immuno-depressed through ionizing radiations, thus making it poss- ible to use adult host animals, not naturally sensitive to the virus, with the advantage of using all types of tissues thereof. Bacterial infections are prevented by antibiotic administration. Virus inactivation is also obtained through ionizing radiations. Radiation doses do not af- fect antigenic properties, as may be noted from the interpretation of the Target Theory.

4959304

P R O D U C T I O N O F M O N O C L O N A L A N T I B O D I E S T O

T R E P O N E M A D E N T I C O L A BY H Y B R I D O M A T D I I I , I I I B B 2

Lloyd Simonson assigned to United States of America as represented by the Secretary of the Navy

A monoclonal antibody is disclosed which is reactive to Treponema denticola and produced by the hybridoma deposited under ATCC HB 9967. The invention also disclosed diagnostic reagents and methods for detecting Treponema denticola utilizing the hybridoma deposited un- der ATCC HB 9967.

4959310

M O N O C L O N A L A N T I B O D I E S T O S O Y B E A N K U N I T Z T R Y P S I N

I N H I B I T O R A N D I M M U N O A S S A Y M E T H O D S

David Brandon, Anne H Bates, Mende Fried- man assigned to The United States of America as represented by the Secretary of Agriculture

Hybrid cell lines (hybridomas) which produce and secrete monoclonal antibodies with three- distinct patterns of recognition are described. The first specificity pattern is defined by anti- bodies which (1) recognize Kunitz trypsin in- hibitor (KTI), one of the principal protease inhibitors found in soybeans, but do not detect the Bowman-Birk inhibitors (BBI), the other major class of protease inhibitors in soybeans; (2) bind to native KTI isoforms a and b but do not react with KTI isoforms a and b which have been denatured by moist heat or alkaline treat- ment or which have been subjected to disulfide exchange; and (3) do not recognize native KTI isoform c. The second specificity pattern is defined by antibodies that (1) recognize KTI, but do not bind BBI; (2) bind native KTI isoforms a and c, but do not bind strongly to KTI isoforms a and c which have been denatured by moist heat or alkaline treatment or which have been sub- jected to disulfide exchange; (3) do not bind KTI isoform b; and (4) bind only weakly to KTI when KTI is complexed with trypsin or a similar en- zyme. The third specificity pattern is defined by antibodies that (1) recognize KTI, but do not bind BBI; (2) bind equivalently to native KTI isoforms a, b, and c, but do not bind to KTI which has been denatured by moist heat or alkaline treatment or which has been subjected to disulfide exchange; and (3) bind equivalently to uncomplexed KTI and KTI complexed with trypsin or a similar enzyme. Immunoassay methods using the monoclonal antibodies to analyze native KTI specifically in soy-derived foodstuffs and in tissues of soybean plants, to determine isoform content of a sample, and to determine the amount of KTI complexed with trypsin in a sample are described.

4959319

P R O C E S S O F C O R N E A L E N H A N C E M E N T

Debra L Skelnik, Richard L Lindstrom

A process for establishing functional human corneal tissue consisting of an enhanced contact- inhibited endothelial monolayer derived from isolated human corneal endothelial cells with other integral corneal layers remaining intact. The process is divided into four integral parts. 1. Isolation of human corneal endothelial cells from donor corneas. 2. Establishment of a human corneal endothelial cell line which in- volves the establishment of primary cell cultures, proliferation, and continued maintenance and subculturing of these cells in vitro. 3. The utiliza-